|
|
Article: US Army to Conduct Phase 2 Trial of Glypromate(R) to Reduce Brain Injury From Cardiac Arrest.
- Article from:
- PR Newswire
- Article date:
- September 4, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Key Points:
- Trial provides entry point to large market for emergency treatment of cardiac arrest and related conditions
- Glypromate(R) for this indication to be submitted for Orphan Drug and Fast Track designation
- Army investigators to submit IND for clinical trial approval
- Trial will give Neuren four cost-effective clinical trials in 2007
SYDNEY, Australia, Sept. 4 /PRNewswire-FirstCall/ -- Neuren Pharmaceuticals today announced that physicians from Madigan Army Medical Center (Madigan) in Tacoma, Washington, will conduct an investigator- initiated Phase 2 trial to determine the safety and efficacy of Glypromate(R) ...